Reinsurer Swiss Re Issues Longevity Drug Guidelines

2025-08-11 02:09:31

(MENAFN- Swissinfo) Reinsurer Swiss Re has introduced guidelines for so-called longevity drugs. Specifically, the guidelines target drugs such as metformin and rapamycin, which were originally developed for other purposes and are used by certain individuals to prolong their lives. This content was published on August 11, 2025 - 16:39 2 minutes Keystone-SDA

+Get the most important news from Switzerland in your inbox

As the long-term effects are still uncertain, Swiss Re has now introduced guidelines for underwriters to assess longevity drugs that show signs of being used, the company announced on Monday. The adjustment is part of the update to the Swiss Re Life Guide from August 2025.

In addition to life-prolonging drugs, the guide has also been expanded to include an improved calculator for chronic kidney disease and prostate cancer risks, as well as enhanced medical risk assessment tools.

More More The Basel researcher whose work triggered a longevity revolution

This content was published on May 7, 2025 Basel-based scientist Michael Hall's discovery of the gene Target of Rapamycin has fuelled one of the fastest growing trends – longevity.

Read more: The Basel researcher whose work triggered a longevity revolutio

MENAFN11082025000210011054ID1109913318

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.